Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New anthracyclines]

M Ogawa1, Y Ariyoshi

  • 1Aichi Cancer Center Hospital.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Idarubicin demonstrates superior efficacy in treating Acute Non-Lymphocytic Leukemia (ANLL) compared to daunorubicin. New anthracyclines and anthrapyrazoles show promise in preclinical and early clinical studies for various cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Present status and clinical therapy of pancreatic diseases].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·1992
Same author

Reptilian viruses: adenovirus-like agent isolated from royal python (Python regius).

Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B·1992
Same author

Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·1992
Same author

Magnocellular neurosecretory neurons with ferritin-like immunoreactivity in the hypothalamic supraoptic and paraventricular nuclei of the rat.

Brain research·1992
Same author

Changes in IL-6, IL-8, C-reactive protein and pancreatic secretory trypsin inhibitor after transcatheter arterial chemo-embolization therapy for hepato-cellular carcinoma.

Cytokine·1992
Same author

Light microscopic immunohistochemical analysis of the distribution of group II phospholipase A2 in human digestive organs.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society·1992
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Idarubicin has demonstrated superior activity against Acute Non-Lymphocytic Leukemia (ANLL) in prospective randomized trials compared to daunorubicin.
  • New anthracycline compounds (SM-5887, KRN-8602, ME-2303) studied in Japan exhibit comparable or superior antitumor activities and lower cardiac toxicities than doxorubicin in preclinical research.
  • Phase II trials are underway for anthrapyrazoles, mitoxantrone analogs, with CI-941 showing notable activity in advanced breast cancer.

Purpose of the Study:

  • To evaluate the efficacy of idarubicin in Acute Non-Lymphocytic Leukemia (ANLL) treatment.
  • To assess the preclinical and clinical potential of novel anthracyclines and anthrapyrazoles in cancer therapy.
  • To report on the activity of CI-941 against advanced breast cancer.

Related Experiment Videos

Main Methods:

  • Prospective randomized trials comparing idarubicin to daunorubicin for ANLL.
  • Preclinical studies evaluating antitumor activities and cardiac toxicities of new anthracyclines versus doxorubicin.
  • Phase II clinical trials of anthrapyrazoles, including CI-941.

Main Results:

  • Idarubicin showed superior activity against ANLL compared to daunorubicin.
  • Preclinical studies indicated that new anthracyclines possess comparable or superior antitumor activities and lower cardiac toxicities than doxorubicin.
  • CI-941 demonstrated excellent activity against advanced breast cancer in Phase II trials.

Conclusions:

  • Idarubicin is a leading treatment option for ANLL.
  • Novel anthracyclines and anthrapyrazoles represent promising therapeutic agents with potential for improved efficacy and safety profiles.
  • CI-941 shows significant potential for treating advanced breast cancer.